Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations

Pharmaceutical Research

Volumn 29, Issue 12, 2012, Pages 3278-3291

  Fang, Wei Jie ^a,c   Qi, Wei ^a   Kinzell, John ^b   Prestrelski, Steven ^b   Carpenter, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Xeris Pharmaceuticals Inc   (United States)

^c Zhejiang Hisun Pharmaceutical Co Ltd   (China)

Author keywords

Excipients; Freeze drying; Peptides; Solid states; Stability

Indexed keywords

BETA CYCLODEXTRIN; GLUCAGON; HETASTARCH; POLYSORBATE 20; SURFACTANT; TREHALOSE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; DRUG STORAGE; DRY POWDER; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TURBIDITY;

DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FREEZE DRYING; GLUCAGON; HORMONES; PROTEIN STRUCTURE, SECONDARY;

EID: 84872075509     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0820-7     Document Type: Article

References (39)

1. Reichert J. Development Trends for Peptide Therapeutics. 2010; Available from: http://www.peptidetherapeutics.org/PTF-report-summary-2010.pdf.
2. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903-18. (Pubitemid 20078439)
3. Manning M, Chou D, Murphy B, Payne R, Katayama D. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
4. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999;88(5):489-500. (Pubitemid 29220973)
5. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation-considerations in the choice of excipients. Expert Opin Drug Deliv. 2009;6(11):1219-30.
6. Carpenter JF, Chang B. Lyophilization of Protein Pharmaceuticals. In: Wu KAaV, editor. Biotechnology and Biopharmaceutical Manufacturing, Processing and Preservation. Buffalo Grove, IL: Intepharm Press; 1996. p. 199-263.
7. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-75. (Pubitemid 27371393)
8. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2008;12(5):505-23. (Pubitemid 350041532)
9. Strickley RG, Anderson BD. Solid-state stability of human insulin i. mechanism and the effect of water on the kinetics of degradation in lyophiles from pH 2-5 solutions. Pharm Res. 1996;13(8):1142-53. (Pubitemid 26279316)
10. Strickley RG, Anderson BD. Solid-state stability of human insulin II. Effect of water on reactive intermediate partitioning in lyophiles from pH 2-5 solutions: stabilization against covalent dimer formation. J Pharm Sci. 1997;86(6):645-53. (Pubitemid 27248813)
11. Wu S-L, Leung D, Tretyakov L, Hu J, Guzzetta A, Wang YJ. The formation and mechanism of multimerization in a freeze-dried peptide. Int J Pharm. 2000;200(1):1-16. (Pubitemid 30177245)
12. Yoshioka S, Miyazaki T, Aso Y. ß-relaxation of insulin molecule in lyophilized formulations containing trehalose or dextran as a determinant of chemical reactivity. Pharm Res. 2006;23(5):961-6. (Pubitemid 43781404)
13. Douglas DB, David MH, Joanna LS, Christine CS, Nicole LS, Himanshu SG. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci. 2009;98(12):4501-10.
14. Matilainen L, Maunu SL, Pajander J, Auriola S, Jääskelä inen I, Larsen KL, et al. The stability and dissolution properties of solid glucagon/?-cyclodextrin powder. Eur J Pharm Sci. 2009;36(4-5):412-20.
15. L'Homme C, Arbelot M, Puigserver A, Biagini A. Kinetics of hydrolysis of fructooligosaccharides in mineral-buffered aqueous solutions: influence of pH and temperature. J Agric Food Chem. 2002;51(1):224-8.
16. Schebor C, Burin L, Buera MDP, Chirife J. Stability to hydrolysis and browning of trehalose, sucrose and raffinose in low-moisture systems in relation to their use as protectants of dry biomaterials. Lebensm Wiss Technol. 1999;32(8):481-5. (Pubitemid 129601566)
17. Garzon-Rodriguez W, Koval RL, Chongprasert S, Krishnan S, Randolph TW, Warne NW, et al. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. J Pharm Sci. 2004;93(3):684-96. (Pubitemid 38332301)
18. Bruce AK. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97(8):2924-35.
19. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, et al. Effect of tween 20 on freeze-thawing-and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci. 1998;87(12):1593-603.
20. Randolph TW, Jones LS. Surfactant-protein interactions. Pharm Biotechnol. 2002;13:159-75.
21. Serno T, Carpenter JF, Randolph TW, Winter GW. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-ß- cyclodextrin. J Pharm Sci. 2010;99(3):1193-206.
22. Matilainen L, Larsen KL, Wimmer R, Keski-Rahkonen P, Auriola S, Järvinen T, et al. The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/γ-CD inclusion complexes. J Pharm Sci. 2008;97(7):2720-9.
23. Granner D, Pilkis S. The genes of hepatic glucose metabolism. J Biol Chem. 1990;265(18):10173-6.
24. Joshi AB, Rus E, Kirsch LE. The degradation pathways of glucagon in acidic solutions. Int J Pharm. 2000;203(1-2):115-25. (Pubitemid 30627632)
25. Joshi AB, Kirsch LE. The relative rates of glutamine and asparagine deamidation in glucagon fragment 22-29 under acidic conditions. J Pharm Sci. 2002;91(11):2331-45.
26. Joshi AB, Sawai M, Kearney WR, Kirsch LE. Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J Pharm Sci. 2005;94(9):1912-27. (Pubitemid 41551476)
27. Beaven GH, Gratzer WB, Davies HG. Formation and structure of gels and fibrils from glucagon. Eur J Biochem. 1969;11(1):37-42.
28. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-83. (Pubitemid 38954214)
29. Webb SD, Cleland JL, Carpenter JF, Randolph TW. Effects of Annealing Lyophilized and Spray-Lyophilized Formulations of Recombinant Human Interferon-γ. J Pharm Sci. 2003;92(4):715-29. (Pubitemid 36396990)
30. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch Biochem Biophys. 1998;360(1):121-34. (Pubitemid 29010921)
31. Dong A, Huang P, Caughey WS. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry. 1990;29(13):3303-8. (Pubitemid 20131472)
32. Dong A, Caughey WS. Infrared methods for study of hemoglobin reactions and structures. Methods: Enzymol. 1994;232:139-75.
33. Coolican SA, Jones BN, England RD, Flanders KC, Condit JD, Gurd RS. [25-Oxindolylalanine]glucagon and [27-methionine sulfoxide]glucagon: preparation, purification, and characterization. Biochemistry. 1982;21(20):4974-81. (Pubitemid 13203096)
34. Nooijen WJ, Kempen HJ. Immunogenicity and bioactivity of glucagon, modified at methionine-27. Horm Metab Res. 1979;11(8):459-63. (Pubitemid 10221155)
35. Tran CD, Beddard GS, Osborne AD. Secondary structure and dynamics of glucagon in solution. Biochim Biophys Acta. 1982;709(2):256-64. (Pubitemid 13156031)
36. Panijpan B, Gratzer WB. Conformational nature of monomeric glucagon. Eur J Biochem. 1974;45(2):547-53.
37. Gratzer WB, Beaven GH. Relation between conformation and association state. J Biol Chem. 1969;244(47):6675-9.
38. Gratzer WB, Creeth JM, Beaven GH. Presence of trimers in glucagon solution. Eur J Biochem. 1972;31(3):505-9.
39. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. Acta Pharm. 2005;55(2):139-56. (Pubitemid 40992426)